• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.

作者信息

Moerman R V, Arends S, Meiners P M, Brouwer E, Spijkervet F K L, Kroese F G M, Vissink A, Bootsma H

机构信息

Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, , Groningen, The Netherlands.

出版信息

Ann Rheum Dis. 2014 Feb;73(2):472-4. doi: 10.1136/annrheumdis-2013-203736. Epub 2013 Aug 12.

DOI:10.1136/annrheumdis-2013-203736
PMID:23940214
Abstract
摘要

相似文献

1
EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.欧洲抗风湿病联盟干燥综合征疾病活动指数（ESSDAI）在一项随机对照试验中对显示利妥昔单抗治疗的疗效很敏感。
Ann Rheum Dis. 2014 Feb;73(2):472-4. doi: 10.1136/annrheumdis-2013-203736. Epub 2013 Aug 12.
2
Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.原发性干燥综合征患者接受利妥昔单抗治疗后疾病活动指数 ESSPRI 和 ESSDAI 的反应性。
Ann Rheum Dis. 2012 Aug;71(8):1297-302. doi: 10.1136/annrheumdis-2011-200460. Epub 2012 Jan 17.
3
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.皮下注射伊纳鲁单抗（VAY736）治疗原发性干燥综合征患者的安全性和有效性：一项随机、双盲、安慰剂对照的2b期剂量探索试验。
Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30.
4
First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.利妥昔单抗治疗干燥综合征患者并发乳糜泻病情改善的首例报告。
Rheumatology (Oxford). 2014 Oct;53(10):1906-7. doi: 10.1093/rheumatology/keu161. Epub 2014 Apr 11.
5
Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?患者摘要。利妥昔单抗对原发性干燥综合征患者有帮助吗？
Ann Intern Med. 2014 Feb 18;160(4):I-11. doi: 10.7326/P14-9005.
6
Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.在原发性干燥综合征患者中，B细胞清除疗法后主要促炎细胞因子减少。
Ann Rheum Dis. 2013 Dec;72(12):2048-50. doi: 10.1136/annrheumdis-2013-203447. Epub 2013 Jul 17.
7
Treatment of primary Sjögren syndrome with rituximab.利妥昔单抗治疗原发性干燥综合征。
Ann Intern Med. 2014 Sep 2;161(5):376-7. doi: 10.7326/L14-5017-3.
8
Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.利妥昔单抗可调节原发性干燥综合征患者唾液腺中白细胞介素-22的表达。
Ann Rheum Dis. 2013 May;72(5):782-3. doi: 10.1136/annrheumdis-2012-202754. Epub 2012 Dec 21.
9
Treatment of primary Sjögren syndrome with rituximab. In response.用利妥昔单抗治疗原发性干燥综合征。作为回应。
Ann Intern Med. 2014 Sep 2;161(5):377-8. doi: 10.7326/L14-5017-4.
10
Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.利妥昔单抗治疗原发性干燥综合征：一项开放标签临床试验及机制分析。
Arthritis Rheum. 2013 Apr;65(4):1097-106. doi: 10.1002/art.37850.

引用本文的文献

1
Efficacy of early rituximab treatment in primary Sjögren's syndrome: a systematic review and meta-analysis.早期使用利妥昔单抗治疗原发性干燥综合征的疗效：一项系统评价和荟萃分析。
J Rheum Dis. 2025 Jul 1;32(3):211-224. doi: 10.4078/jrd.2024.0149. Epub 2025 Feb 24.
2
The Development and Content Validation of the Sjögren's Related Quality of Life Instrument (SRQoL).干燥综合征相关生活质量量表（SRQoL）的开发与内容效度验证
Rheumatol Ther. 2024 Dec;11(6):1591-1609. doi: 10.1007/s40744-024-00718-6. Epub 2024 Oct 10.
3
Investigative biological therapies for primary Sjögren's syndrome.
原发性干燥综合征的研究性生物疗法。
Arch Med Sci. 2020 Jul 15;20(2):506-516. doi: 10.5114/aoms.2020.97288. eCollection 2024.
4
Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.对患者和医生进行定性研究，以评估干燥综合征中ESSDAI和ESSPRI的内容效度及有意义的变化。
Rheumatol Ther. 2022 Dec;9(6):1499-1515. doi: 10.1007/s40744-022-00487-0. Epub 2022 Sep 16.
5
ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts.ESSDAI 活动指数的 SJÖGRENSER 队列：分析及与其他欧洲队列的比较。
Rheumatol Int. 2019 Jun;39(6):991-999. doi: 10.1007/s00296-019-04285-w. Epub 2019 Mar 19.
6
Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome.原发性干燥综合征中与疾病活动相关的确定性血清生物标志物的鉴定。
Arthritis Res Ther. 2016 May 14;18(1):106. doi: 10.1186/s13075-016-1006-1.
7
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.原发性干燥综合征临床试验的入选标准：来自英国原发性干燥综合征注册库的经验教训。
Rheumatology (Oxford). 2016 Mar;55(3):544-52. doi: 10.1093/rheumatology/kev373. Epub 2015 Oct 27.
8
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.欧洲抗风湿病联盟干燥综合征疾病活动指数（ESSDAI）：使用指南。
RMD Open. 2015 Feb 20;1(1):e000022. doi: 10.1136/rmdopen-2014-000022. eCollection 2015.
9
Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?在随机对照试验中应纳入哪些患者以及多少患者，才能证明生物制剂治疗原发性干燥综合征的疗效？
PLoS One. 2015 Sep 14;10(9):e0133907. doi: 10.1371/journal.pone.0133907. eCollection 2015.
10
Biomarkers: new biomarker for Sjögren's syndrome--time to treat patients.生物标志物：干燥综合征的新型生物标志物——是时候治疗患者了。
Nat Rev Rheumatol. 2013 Oct;9(10):570-2. doi: 10.1038/nrrheum.2013.143. Epub 2013 Sep 17.